Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer.
Phase of Trial: Phase IV
Latest Information Update: 17 Apr 2013
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Cancer metastases; Prostate cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 10 Jun 2017 Biomarkers information updated
- 13 Feb 2013 New source identified and integrated (German Clinical Trials Register; DRKS00004021).
- 12 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.